Surface Ophthalmics

News

News

View the latest company news from Surface Ophthalmics.

  • March 13, 2024
    Surface Ophthalmics Announces New Leadership with Richard Lindstrom, MD, and Renewed Vision for Addressing Critical Unmet Needs of Dry Eye Syndrome Patients
  • July 21, 2021
    Surface Ophthalmics Announces $25 Million Private Round of Fundraising
  • May 6, 2021
    Surface Ophthalmics’ Landmark Chronic Dry Eye Study Reaches 50% Enrollment Milestone
  • March 31, 2021
    Surface Ophthalmics Announces Preeya K. Gupta, MD as Chief Medical Advisor
  • February 4, 2021
    Surface Ophthalmics Announces First Patient Dosed in Phase II Trial for SURF-200 for Acute Dry Eye
  • January 27, 2021
    Surface Ophthalmics Announces First Patient Dosed in Landmark Head-to-Head Phase II Trial for SURF-100 for Chronic Dry Eye Disease
  • January 21, 2021
    Surface Ophthalmics Announces Positive Top-Line Results from Phase II Trial for SURF-201 (Betamethasone 0.2% in Klarity® vehicle) for the Treatment of Post-Cataract Surgery Pain and Inflammation
  • January 7, 2021
    Surface Ophthalmics Previews Important Clinical Progress in 2021
  • October 1, 2020
    Surface Pharmaceuticals Further Strengthens Board of Directors as Clinical Programs Advance
  • September 3, 2020
    Surface Pharmaceuticals Strengthens Leadership Team as Clinical Programs Advance in Eye Care
  • May 15, 2018
    Surface Pharmaceuticals, Inc. Announces $20 Million Series A Financing From Flying L Partners
  • October 24, 2017
    Imprimis Launches Surface Pharmaceuticals Subsidiary